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Table 1
Patient demographics and baseline disease-related characteristics
Characteristic No GVHD
(n¼26)
GVHD
(n¼45)
Age at transplant (years) (median, IQR) 48 (32-57) 49 (34-56)
Gender (male) 13 (50%) 29 (64%)
Race
White 25 (96%) 34 (76%)
Black 1(4%) 10 (22%)
Other 0 (0%) 1 (2%)
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prophylaxis consisted of Cy (50 mg/kg/day on days 3 and 4),
tacrolimus (days 5 to 180), and mycophenolate mofetil (days
5 to 60). Our primary endpoint was the incidence of non-
relapse mortality (NRM) at day 100. Secondary endpoints
included overall survival (OS), disease-free survival (DFS),
the incidence of engraftment, acute GVHD, and relapse.
Results: Median age was 48 (range 21-65) with 22 male and
9 female. Diagnosis of the patients included AML (n¼17),
ALL/LBL (n¼8), MDS/MPN (n¼4), and lymphoma (n¼2). The
majority (61.3%) of patients were not in remission and 13
patients (41.9%) had a history of prior allogeneic stem cell
transplantation (allo-SCT). Twenty-seven patients (87.1%)
engrafted with median neutrophil engraftment on 19 days
(range 15-27). The cumulative incidence of grades II-IV and
III-IV acute GVHD at day 100 was 22.6% (95% CI, 9.8-38.6%)
and 3.2% (95% CI, 0.2-14.4%), respectively. NRM at day 100
was 19.4% (95% CI, 7.7-34.9%). Cumulative incidence of
relapse at day 100 was 19.4% (95% CI, 7.7-35.0%). With a
median follow-up of 171 days, OS and DFS was 74.2% (95% CI,
55.0-86.2%) and 61.3% (95% CI, 42.0-75.8%), respectively, at
day 100. Subgroup analysis showed that patients who had a
history of prior allo-SCT had higher NRM (30.8% vs. 11.1%,
p¼0.07) and less lower OS (53.8% vs. 83.9%, p¼0.03) than
those in patients without a history of prior allo-SCT.
Conclusions: Our results suggest that posttransplant Cy
based HLA-haploidentical PBSCT after busulfan containing
reduced-intensity conditioning achieves stable donor
engraftment and low incidence of GVHD. NRM was accept-
able in the setting of the ﬁrst allo-SCT. Given the promising
results of GVHD and NRM, phase II study inmuch larger scale
are now under investigation.Ethnicity (Non-Hispanic) 26 (100%) 43 (96%)
Primary disease
ALL,AML,MDS 14 (54%) 24 (53%)
CML,CLL 4 (15%) 5 (11%)
Lymphoma 5 (19%) 11 (24%)
Other 3 (12%) 5 (11%)
Prior allogeneic HSCT 2 (8%) 3 (7%)
Donor
Match-related 6 (23%) 15 (33%)
Mismatch-related 7 (27%) 8 (18%)
Match-unrelated 6 (23%) 17 (38%)
Mismatch-unrelated 7 (27%) 5 (11%)
Cell source
Peripheral blood stem cells 19 (73%) 40 (89%)
Cord 7 (27%) 5 (11%)
Conditioning
Myeloablative 3 (12%) 7(16%)
Reduced intensity 23 (88%) 38 (84%)
GVHD prophylaxis
T-cell depletion (alemtuzumab) 12 (46%) 24 (53%)
Methotrexate + Tacrolimus 5 (19%) 13 (29%)
Mycophenolate + Tacrolimus 9(35%) 8 (18%)
Acute GVHD before endoscopy 16 (62%) 33 (73%)
Chronic GVHD before endoscopy 3 (12%) 6 (13%)
Table 2
Signs and symptoms (at endoscopy)
Characteristic No GVHD
(n¼26)
GVHD (n¼45)
Time from transplant (days)
(median, IQR)
188 (136-288) 160 (127-273)
Anorexia 10 (38%) 24 (53%)
Abdominal pain or cramping 11 (42%) 27 (60%)
Nausea or vomiting 16 (62%) 28 (62%)
Diarrhea 14 (54%) 39 (87%)
Weight loss (kg) (median, IQR) 8.3 (2.7-26.4) 13.7 (8.5-22.4)
Albumin change (median, IQR) -0.2 (-0.7-+0.4) -0.4 (-1.1-+ 0.3)
Platelet count (median, IQR) 98 (58-167) 118 (77-173)
Bilirubin (median, IQR) 0.6 (0.5-0.85) 0.7 (0.6-1.2)454
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Introduction: Gastrointestinal (GI) complications are com-
mon after allogeneic hematopoietic stem cell transplantation
(HSCT) and contribute to signiﬁcant morbidity andmortality.
Although the ﬁrst 100 days are typically considered the
“acute” period after a transplant, many GI events occur after
this time. These include “acute” GVHD (now reclassiﬁed as
late acute GVHD), classic chronic GVHD, and overlap syn-
drome, as well as infections, ulcers, drug reactions, andmore.
In order to shed light on the problem of late GI complications
after HSCT, we performed a single institution retrospective
study of HSCT patients requiring endoscopy after Day 100.
Methods: We identiﬁed 397 patients who underwent allo-
geneic HSCT between 1/1/05-12/31/10. Of these, 176 (44%)
had an endoscopic evaluation post-HSCT, including 79 with
endoscopies performed after Day 100. Eight of these were
performed for known conditions (e.g., follow up of previous
GI bleed, screening colonoscopy at 3 years), leaving 71 pa-
tients (18%) who had endoscopies for late GI symptoms. In
addition to reviewing these charts, biopsies were re-
reviewed by two pathologists, blinded to clinical ﬁndings, toensure uniform categorization in light of the NIH Consensus
Criteria (Biol Blood Marrow Transp 2005;11:945-955). In
addition to diagnosis, outcomes included overall survival
(OS) and treatment-related mortality (TRM).
Results: Of 71 patients with late GI complications requiring
endoscopy, 45 (63%) had GI GVHD [late acute: 39 (87%),
classic chronic: 1 (2%), overlap: 5 (11%)]. Of the 26 without
GVHD, the most common diagnoses were: infection (8: 6
CMV, 1 C diff, 1 unknown), gastritis/duodenitis (7), drugs
(one each on mycophenolate and valgancyclovir), local dis-
ease relapse (2), delayed motility (1), and unknown (6).
Baseline characteristics (Table 1) and signs and symptoms at
endoscopy (Table 2) were generally similar in both groups
with the exception of diarrhea which was more common in
patients with GVHD (87% vs. 54%, p¼0.01). While
multivariate logistic regression analysis showed apoptosis
score (1-4) was predictive of GVHD (OR¼2.35, 95% CI 1.18-
4.70), crypt destruction was predictive of need for TPN
(OR¼2.56, 95% CI 1.37-4.81). Patients with GVHD tended to
shorter overall survival (e.g., 2-year OS of 31% vs 50%) than
Figure 1.
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treatment-related mortality (Figure 1, p¼0.119).
Conclusion: Late GI complications are common after HSCT,
with 18% of patients requiring endoscopy after Day 100. Few
clinical characteristics distinguish GVHD from other etiol-
ogies and endoscopy is essential to establishing the diag-
nosis. Findings of crypt destructionmay predict severe GVHD
and need for TPN.
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Introduction: Hematopoietic stem cell transplantation
(HSCT) still remains the only curative treatment for patients
suffering from severe forms of sickle cell disease (SCD). The
aim of this studywas to review the indications and outcomes
of SCD children transplantedwith a matched sibling donor at
a medium sized pediatric institution in Canada.
Methods: From 2003 to 2014, 17 children received a HSCT at
our institution. Data were retrospectively extracted from
medical charts.
Results: All children had severe forms of SCD including
stroke (3/17), silent strokes (7/17), cerebral artery stenosis
(9/17), acute chest syndrome (10/17), splenic sequestration
(5/17) and recurrent vaso-occlusive crisis requiring up to 41
hospital admissions for one patient. Neurocognitive impair-
ment was documented for 7 out of 11 children tested. Before
HSCT, 10/17 children had been treated by programmed blood
transfusions and 12/17 had received hydroxyurea. Children
transplanted after 2010 tended to be younger and to have
less brain damage. The median age at HSCT was 10y (2 to15y). The myeloablative conditioning regimen was based on
Busulfan, Cyclophosphamide and rabbit antithymoglobulin.
The source of stem cells was a bone marrow for 11 patients
and a cord blood for 6.
The median follow-up was 56 months (128 to 4m). All
patients engrafted. Stable mixed chimerism (less than 95% of
donor cells) was common (13/17). No patient experienced
new onset of SCD complications. Previous organ damages did
not progress after HSCT. No grade 2-4 acute graft versus host
disease (GVHD) was observed. Extensive chronic GVHD was
noted for 2 out of 16 patients and evolved favorably on
treatment. At 12 months after HSCT, 10 out of 11 children
were free from immunosuppressive drugs. Opportunistic
infections were common such as CMV (12/17) or EBV (13/13),
and evolved favorably with or without treatment. One death
not related to HSCToccurred 42 months after HSCT. Among 5
evaluable women, 2 have primary amenorrhea, 2 have some
signs of ovarian insufﬁciency and the youngest one (5 years
old at HSCT) has a normal ovarian function.
Conclusion: HSCT with a matched sibling donor is safe and
effective to cure children suffering from SCD, whatever the
graft source is a bone marrow or a cord blood. The outcomes
at our medium-sized Canadian institution are identical to the
best results from larger institutions. A younger age at HSCT
may enhance the functional prognosis of severe SCD and may
decrease the risk of long term gonadal toxicity related to HSCT.456
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Background: Ruxolitinib (Rux) is a potent, oral JAK inhibitor
that is approved for treatment of intermediate- or high-risk
myeloﬁbrosis (MF). Several groups reported on Rux use
before alloSCT with primary goals of splenomegaly and
constitutional symptom reduction. There are no data on Rux
posttransplant.
Methods: We retrospectively analyzed the outcomes of pa-
tients diagnosed with MF at University of Massachusetts
Medical Center who received Rux before and post alloSCT
(between 6/2013 and 8/2014).
Results: Four patients (2 females)were identiﬁed;median age
was76 years (49-83) at diagnosis. One patient had primaryMF,
3 had secondaryMF. Onehad secondaryAMLwithpost PV-MF,
1 had secondary MDS with MF and one had chronic myelo-
monocytic leukemiawithMF. All had constitutional symptoms
at diagnosis. Three patients had splenomegaly, 1 had surgical
splenectomy before alloSCT. Three patients had received Rux
before alloSCT. The median time from Rux to alloSCT was 4
months (0.4-4.9). Two patients received RIC regimen (Flu-
darabine/Bu2/ATG) and 2 received Thiotepa/Fludarabine/
Melphalan with posttransplant cyclosphosphamide. Neutro-
phils engraftedwithmedian 16 days (12-23). All patientswere
transfusion independent at day 30 (D30) with >97% donor
chimerism in BM. Following the alloSCT Rux was started with
median 2.2 months (0.4-8.8) from alloSCT. CMV viremia was
detected in one patient before day 100 and one had suspected
VZV reactivation at 12 months, in both cases Rux was
continued. No EBV reactivation or fungal infection was seen.
Three pts had a brief episode of aGVHD (grade I, I and III) of the
skin that responded to steroids and immunosuppression taper.
